Filing Flows › Lineage Cell Therapeutics (LCTX) › Q1 2026 › vs Q1 2025
Lineage Cell Therapeutics (LCTX) Q1 2026 vs Q1 2025 (year over year)
Lineage Cell Therapeutics's revenue rose $223K (+15%) from $1.5M in Q1 2025 to $1.7M in Q1 2026. The biggest changes: Royalties License and Other Revenues −$82K (-35%).
Lineage Cell Therapeutics, Q1 2026: revenue $1.7M (+15% year over year), operating margin -440.2%, net loss $4.8M, operating cash flow −$8.1M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Upfront License Fees | $860K | $1.3M | −$410K | -32% |
| Royalties License and Other Revenues | $150K | $232K | −$82K | -35% |
| Revenue | $1.7M | $1.5M | $223K | +15% |
| Other income, net | $2.8M | $2.4M | $442K | +19% |
| Net loss | $4.8M | $4.1M | $646K | +16% |
| Costs & expenses | $9.3M | $8.0M | $1.3M | +16% |
| Operating costs | $9.3M | $8.0M | $1.3M | +16% |
| Research & development | $4.2M | $3.1M | $1.1M | +36% |
| General & admin | $5.1M | $4.9M | $227K | +5% |
| Operating cash sources | $9.4M | $6.3M | $3.2M | +51% |
| Depreciation & amortization | $188K | $164K | $24K | +15% |
| Share-based compensation | $1.2M | $1.2M | −$45K | -4% |
| Cash used in operations | $8.1M | $4.9M | $3.2M | +65% |
| Net loss absorbed | $4.8M | $4.1M | $646K | +16% |
| Working capital & other | $4.6M | $2.1M | $2.5M | +119% |
Questions
How much did Lineage Cell Therapeutics's revenue grow year over year in Q1 2026?
Lineage Cell Therapeutics's revenue rose $223K (+15%) from $1.5M in Q1 2025 to $1.7M in Q1 2026.
What drove Lineage Cell Therapeutics's revenue change in Q1 2026?
Royalties License and Other Revenues −$82K (-35%).